AstraZeneca’s Etcamah Combination Falls Short of Statistical Significance in SERENA-4

The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.